Phase 3 N=33 Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria
Acute Urticaria
Primary: Extent of Urticaria/Erythema Score (Physician Assessment) — 1.91; 1.74; 1.53; 1.12 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=17 Belimumab in Idiopathic Inflammatory Myositis
Myositis
Primary: Response Rate During Randomized Phase — 3; 1; 5; 2 Participants — p=0.60
N/A N=24 Safety and Feasibility of Atrial Deganglionation as Adjunctive Therapy for AF
Atrial Fibrillation
Primary: Number of Participants With Device-related Primary Safety Adverse Events — 0 Participants
Phase 3 N=44 Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome
Complex Regional Pain Syndrome
Primary: Pain Score — 5.9; 6.0; 6.5; 6.8 score on a scale — p=0.19
N/A N=372 Examination of Low Wattage and High Wattage E-Cigarettes
Smoking, Cigarette · Smoking, Tobacco · Nicotine Dependence
Primary: Complete Change From Conventional Cigarettes - Self Report — 0; 12; 10; 0 Participants
Phase 3 N=425 A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Area Under the Curve From Time 0 Over the Dosing Interval (AUCtau) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group) — 1458.03; 1472.68 hr*μg/mL
Phase 3 N=223 A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
Epilepsy, Partial
Primary: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period — -66.4; -47.8; -66.4 percentage of change
N/A N=103 Addiction and Behavior Related to Menthol Cigarette Substitutes
Smoking (Tobacco) Addiction
Primary: Puffing Topography: Puff Duration — 1.99; 2.06; 2.66; 1.87 seconds
Phase 1 N=28 CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Multiple Myeloma
Primary: Number of Participants Evaluated for Vaccine Safety — 13; 15 Participants
N/A N=6,767 Reverse Innovation and Patient Engagement to Improve Quality of Care and Patient Outcomes
Diabetes · Cardiovascular Disease · Substance Abuse Disorder
Primary: Change in Emergency Department Visits + Hospital Days — -0.0069; 0.0113 Diff in monthly hospital days+ED visits — p=0.63
Phase 1 N=20 The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
Drug Drug Interaction
Primary: Cmax of Givinostat, Following Single Doses of the Parent Drug — 53.57; 75.35 ng/mL
Phase 3 N=1,708 Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults
Rabies · Healthy Volunteers
Primary: Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titer Greater Than or Equal to (>=) 0.5 IU/mL — 100; 100; 100; 100…
N/A N=18 A Study Using Transorbital Alternating Current Stimulation for People With Glaucoma
Glaucoma
Primary: Change in Peripapillary RNFL Thickness — -0.13; -1.8 micrometers (μm)
Phase 3 N=57 A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
Guillain-Barre Syndrome
Primary: Time to First Reaching a Hughes Functional Grade (FG) Score <=1 — 112.0; 168.0 Days — p=0.8938
Early Phase 1 N=21 Reduced Nicotine Cigarette Purchasing Decisions
Tobacco Use Disorder
Primary: Demand Intensity — 6.48; 8.10; 7.81; 6.48 cigarettes